{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '3.', 'INTRODUCTION', 'The inflammation associated with COPD is characterized by a prominent infiltration of', 'neutrophils in lung tissue and the airways. Neutrophils and other inflammatory cells are', 'recruited to the lung in response to various chemotactic factors, including chemokines.', 'Specifically, there is a large body of evidence that the CXCR2 chemokine receptor plays', 'a pivotal role in neutrophil recruitment to the lung. For neutrophils, chemokine binding', 'to the CXCR2 results in chemotaxis and cell activation, ultimately resulting in the release', 'of a number of inflammatory mediators and proteases that are thought to contribute to the', 'progressive fibrosis, airway stenosis, and destruction of the lung parenchyma', 'characteristic of COPD.', 'Selective antagonism of the interaction between CXCR2 and its ligands is a potential', 'strategy for reducing the inflammation in COPD [Chapman, 2009]. A reduction in tissue', 'and airway neutrophilia is expected to result in downstream effects on mucus', 'hypersecretion, lung inflammation, and tissue destruction that are hypothesized to', 'underlie the development and worsening of respiratory symptoms and decline in lung', 'function that occurs in COPD.', 'Molecules with CXCR2 antagonist activity have been shown to reduce the influx of', 'neutrophils into the lungs in healthy participants (e.g. ozone or LPS challenge models)', 'and to reduce sputum and tissue neutrophils in the lungs of patients with severe,', 'neutrophilic asthma, COPD and bronchiectasis in association with improvements in', \"measures of disease activity in some, but not all, studies O'Byrne, 2016; Holz, 2010;\", 'Watz, 2016; Lazaar, 2011; Nair, 2012; Rennard, 2015]. Overall, the results of the', 'reported clinical studies with CXCR2 antagonists suggest that careful selection of the', 'target patient population is important to achieving clinical benefit.', 'Danirixin is a selective CXCR2 antagonist being developed as a potential anti-', 'inflammatory agent for the treatment of COPD and other inflammatory diseases and', 'influenza. Danirixin has demonstrated potent antagonism of CXCR2 activity both in', 'vitro and in vivo in preclinical studies GlaxoSmithKline Document Number', 'YM2010/00163/07]', 'Clinical pharmacology studies in healthy volunteers demonstrated the pharmacodynamic', 'activity of danirixin (inhibition of ex vivo CXCL1-induced CD11b expression on', 'peripheral blood neutrophils). Danirixin has also been tested in a Phase IIa study in', 'symptomatic participants with mild to moderate COPD at risk for exacerbation', '[GlaxoSmithKline Document Number 2013N180289 03 Study ID 200163]. In study', '200163, twice daily dosing with danirixin free base (75 mg bid) or placebo given on top', 'of standard of care inhaled maintenance treatments was tested for one year. Analyses of', 'clinical endpoints from study 200163 demonstrated that danirixin, compared to placebo,', 'reduced respiratory symptoms as measured with E-RS:COPD [Miller, 2016].', '3.1.', 'Study Rationale', 'This protocol describes a pilot study to investigate the effect of danirixin HBr 35mg', 'tablets on lung function and health related quality of life (HRQoL) in participants with', '12']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'mild to moderate airflow obstruction identified from the COPDGene cohort. Study', 'participants will continue with their standard of care inhaled medications (i.e. long acting', 'bronchodilators with or without inhaled corticosteroids) while receiving study treatment.', 'Specifically, this study aims to assess whether or not danirixin has the potential to impact', 'disease progression in participants with a COPD progression score indicating they are', 'likely to decline based on 5 year data from COPDGene and support the conduct of a', 'larger Phase III study for disease progression. In addition to lung function and HRQoL,', 'this study will assess moderate/severe COPD exacerbations, health status (CAT), and', 'rescue medication use.', '3.2.', 'Background', 'COPD is a major cause of disability, morbidity, and mortality, resulting in millions of', 'deaths annually worldwide contributing significantly to health care costs [Mathers, 2006;', 'Lopez-Campos, 2016; Vastava, 2015; GOLD, 2016]. The morbidity and mortality of', 'COPD are continuing to increase and worldwide and, by the year 2020, COPD is', 'expected to be the third leading cause of death and fifth leading cause of disability', '[Mathers, 2006; Lopez-Campos, 2016]. The airflow limitation that characterizes COPD', 'is primarily due to small airways disease and parenchymal destruction associated with an', 'excessive inflammatory response in the lung, mainly caused by cigarette smoking [Celli,', '2004]. COPD is characterized by symptoms of chronic and, in many patients,', 'progressive breathlessness (or dyspnea), cough and sputum production. Many COPD', 'patients also suffer from periodic worsening of their COPD symptoms that is beyond the', 'typical day to day variation [Hurst, 2010]. These episodes of worsening symptoms', '(COPD exacerbations) account for a significant proportion of COPD-related and total', 'health care costs. Despite several available therapies that have been shown to reduce', 'COPD exacerbations and respiratory symptoms, many COPD patients continue to', 'experience a high burden of respiratory symptoms and COPD exacerbations resulting in a', 'continuing unmet medical need [Vestbo, 2016]. Additionally, there is growing', 'recognition that a high percentage of COPD patients with mild airflow limitation as well', 'as smokers with preserved lung function suffer from a high burden of symptoms and', 'COPD exacerbations with a subsequent impact on health status [Woodruff, 2016].', 'Therapies that effectively further reduce COPD exacerbations and improve respiratory', 'symptoms could have a substantial impact on healthcare utilization and most importantly', \"result in an improvement in COPD patients' quality of life.\", 'The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the', 'treatment and management of patients with COPD recommend that the management of', 'current respiratory symptoms and subsequent worsening of symptoms resulting in COPD', 'exacerbations should be an important component of COPD patient management [GOLD,', '2016].', 'Danirixin is being evaluated as an addition to standard of care inhaled therapies (i.e. long', 'acting bronchodilators and long acting bronchodilator/corticosteroid combination', 'therapies) and is targeting those COPD patients that continue to have a burden of', 'respiratory symptoms and COPD exacerbations despite management with currently', 'available COPD treatments.', '13']\n\n###\n\n", "completion": "END"}